Bristol Myers Squibb (BMS) is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’ interleukin-12 (IL-12) immunotherapy program.
This program is the early-stage experimental med DF6002, a monovalent IL-12 immunoglobulin Fc fusion protein, which works by creating an inflammatory tumor microenvironment to boost anti-tumor responses.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,